Endo IncOTCQX US:NDOI
- LAST PRICE25.1500
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots25.0100/ 1
- Ask / Lots25.1600/ 1
- Open / Previous Close--- / 25.1500
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | NDOI |
|---|---|---|
| 11:06 ET | 100 | 25.16 |
| 11:29 ET | 100 | 25.15 |
Sep 13, 2024
Endo Presents Data at the American Orthopaedic Foot & Ankle Society Annual Meeting, from 7:30AM ET on Friday Sep 13, 2024 by Dow Jones
7:30AM ET on Friday Sep 13, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Endo Inc | 1.9B | 0.4x | --- |
Mallinckrodt PLC | 1.6M | 0.0x | --- |
Amneal Pharmaceuticals Inc | 2.7B | -13.8x | --- |
Prestige Consumer Healthcare Inc | 3.5B | 17.1x | --- |
Emergent BioSolutions Inc | 496.4M | -0.8x | --- |
Tilray Brands Inc | 1.5B | -5.0x | --- |
Company Information
Endo, Inc. is a diversified specialty pharmaceutical company, which is engaged in transforming insights into life-enhancing therapies. The Company’s segments include Branded Pharmaceuticals, Sterile Injectables, Generic Pharmaceuticals, and International Pharmaceuticals. Its Branded Pharmaceuticals segment focuses on products that have inherent scientific, regulatory, legal and/or technical complexities and are marketed under recognizable brand names that are trademarked. Its Sterile Injectables segment includes a broad portfolio of approximately 40 critical care, maternal health, anesthesia and other products. Its Generic Pharmaceuticals segment includes a portfolio of approximately 85 generic product families, including solid oral extended-release products, solid oral immediate release products, liquids, semi-solids, and others. Its International Pharmaceuticals segment sells a variety of specialty pharmaceutical products outside the United States, primarily to customers in Canada.
Contact Information
- Headquarters
- 1400 Atwater DriveMALVERN, PA, United States 19355
- Phone
- 484-216-0000
- Fax
- 302-655-5049
Executives
- Independent Chairman of the Board
- Paul Herendeen
- President, Chief Executive Officer, Director
- Blaise Coleman
- Chief Financial Officer, Executive Vice President
- Mark Bradley
- Executive Vice President, Chief Legal Officer, Secretary
- Matthew Maletta
- Executive Vice President, President, Global Commercial Operations
- Patrick Barry
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $1.9B |
|---|---|
Revenue (TTM) | --- |
Shares Outstanding | 76.4M |
Endo Inc does not pay a dividend. | |
Beta | --- |
EPS | --- |
Book Value | $-86.36 |
P/E Ratio | 0.4x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
